Beijing, China - Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ('Biocytogen', stock code 02315.HK), an international biotechnology company that drives the research and development of new antibody drugs with innovative technology, today Announced a collaboration with ABL Bio Inc. ('ABL', KOSDAQ: 298380), a South Korean biotechnology company developing novel therapies for oncology and central nervous system diseases in clinical stages, to jointly develop novel bispecific antibody drug conjugates (bisAbs) ADC).
Biocytogen's RenLite mouse platform generates fully human antibodies with high affinity that recognize different epitopes. The platform features the generation of common light chain antibodies, enabling the development of dual-antibody ADCs with design flexibility, simple production processes and good druggability. Based on this platform, future cooperation between the two parties may be expanded to the development of different forms of ADC drugs.
Dr. Shen Yuelei, Chairman and CEO of Biocytogen, said: 'We are very pleased to reach a cooperation with ABL. ABL has advanced cancer immunotherapy and central nervous system disease treatment platforms. They continue to successfully advance pipeline research and development, demonstrating excellent performance in regulatory, clinical development and Professionalism and capabilities in business development. The dual anti-ADC drugs derived from the RenLite platform have shown better efficacy in a variety of tumor models and have good safety profiles. We believe that we have high tumor selectivity and target synergy The dual-antibody ADC platform technology featuring endocytosis and simple CMC development will effectively complement the advantages of ABL. We will work together to accelerate the development of new dual-antibody ADC therapies.'
Sang Hoon Lee, CEO of ABL, said: 'We are very excited to establish a cooperation with Biocytogen to jointly develop dual-antibody ADCs. This cooperation is an important step in our efforts to develop dual-antibody ADC drugs. We look forward to a fruitful cooperation and firmly believe that this cooperation will Help us develop a differentiated pipeline and ultimately develop novel therapies that improve patients' quality of life.'
About Biocytogen
Biocytogen (stock code: 02315.HK) is an international biotechnology company driven by innovative technology to develop new drugs, and is committed to becoming the birthplace of new drugs in the world. Based on the underlying gene editing technology, Biocytogen independently developed the RenMice (RenMab, RenLite, RenNano, RenTCR-mimic TM) platform for fully human therapeutic monoclonal antibodies, bi/multispecific antibodies, and dual antibodies. Discovery of ADCs, Nanobodies and TCR-like antibodies. Biocytogen is conducting large-scale drug development for more than 1,000 potentially druggable targets ('Thousands of Rats and Tens of AntibodiesTM ' plan), and has established a library of more than 400,000 fully human antibody sequences for global collaboration. As of June 30, 2023, Biocytogen has signed 50 drug cooperative development/authorization/transfer agreements and reached 42 target project RenMice platform authorized development cooperation with companies, including multiple MNCs; multiple Clinical stage antibody molecules have also reached external licensing cooperation. The company's sub-brand BioMice provides thousands of gene-edited animal and cell models, including target humanized mice, and also provides preclinical pharmacology and gene editing services to customers around the world. Biocytogen is headquartered in Beijing and has branches in China (Haimen, Jiangsu, Shanghai), the United States (Boston, San Francisco) and Heidelberg, Germany.
About ABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company focused on the development of antibody therapies for immuno-oncology and neurodegenerative diseases. Based on independent research and development and global cooperation, ABL has developed a variety of dual-antibody platforms, such as Grabody-T and Grabody-B, and established an innovative pipeline consisting of a variety of clinical and preclinical drug candidate molecules. In the area of oncology, we developed Grabody-T, a modular 4-1BB adapter platform that demonstrated excellent efficacy and safety. In the field of neurodegenerative diseases, we have developed Grabody-B to maximize blood-brain barrier crossing. Grabody-B is applicable to different central nervous system targets in multiple neurological diseases and has the potential to bring breakthroughs in highly unmet medical needs in neurodegenerative diseases.
Contact:
Email: pr@bbctg.com.cn
Tel: 010-56967601
Email: ir@bbctg.com.cn
ABL BIO INC. 
